Nike has to be the most hotly anticipated earnings report due this week. With all eyes on the multinational shoe-giant it will be interesting to see how the tensions between China and the US will impact the outcome. With Trump and Xi due to meet at the G20 summit in Japan this weekend, the outcome of their talks is set to have a huge impact on apparel and footwear markets. If things don’t go well, we could see Trump slapping more tariffs on Chinese goods which could have a big effect on Nike who make many of their products in China. Nike is expected to report earnings of 66 cents per share and a revenue of $10.16 billion. Despite this, some analysts have said that due to stalling growth and other uncertainties, Nike is not a good buy for now. That said, it seems like many think it has the potential to bounce back in 2020.
Investors are expecting to see a year-over-year increase in earnings when Accenture releases its earnings report for the last quarter today. Zacks has estimated that the consulting company will post quarterly earnings of $1.88 per share in today’s report, marking a year-over-year increase of 5%. That said, the current consensus EPS estimate sits at 0.51% lower over the 30 days, when compared to the current level. Zacks has also given an estimate for revenues at $11.01 billion, a growth of 6.8% over the year.
McCormick & Co (MKC)
Analysts on Wall Street are expecting to see earnings of $1.08 per share on revenue of $1.3 billion. During the same quarter last year, they reported earnings of $1.02 on sales of $1.3 billion. This means there has been a 5.88% increase year-over-year in the companies earnings whilst revenue is down 1.28%. With shares up 43.26%, the average rating of analysts on MKC stock is neutral and has remained as such over the last 90 days.
Walgreens Boots Alliance (WBA)
The pharmacy chain giant Walgreens Boots Alliance is set to release third-quarter fiscal earnings today. The pharmacy sector has suffered recently, but during the last quarter, its earnings outperformed the Zacks Consensus Estimate and there are hopes it will do so again. An influx of prescriptions from Rite Aid are expected to positively contribute to Walgreen Boots’ top line, despite low pharmacy margins and a decrease in front-end comparable sales. Zacks has pegged its estimate at $26.16 billion, a rise of 0.95% from the figure reported this time last year.